Skip to content
Vanity or Vice
Start a decision

Routines & Ingredients

Bakuchiol Is Not Plant Retinol. One Solid Trial Does Not Make a Category

An amber glass dropper bottle lying on a plain bone-coloured surface beside a single slender meadow grass stem in soft daylight.

Bakuchiol is sold as the gentler, plant-derived answer to retinol. Wanting wrinkle and pigment improvement without the peeling and irritation is completely understandable. The evidence is narrower than the marketing.

Parallel path, not identical mechanism

Bakuchiol is a meroterpene phenol from Psoralea corylifolia. It can influence some retinol-adjacent gene-expression pathways, but it is not a retinoid and does not work by simply becoming “plant retinol.” That distinction matters because a similar-looking outcome does not make the molecules interchangeable.

METHOD · EVIDENCEWhere the proof is standing.Systematic reviewRandomised trialSmall human trialCase seriesAnimal modelIn vitroWHAT A VERDICT WANTSPeople, randomised, followed longenough for the effect to be realrather than new.WHAT THE BOX USUALLY CITESReal research, but a long way fromyour face. Useful as a reason tolook, never as proof.Nothing here is worthless. The question is only ever how far it is from the promise on the label.
Where the proof is standing. The ordinary hierarchy of study design. Marketing tends to cite the lower half and describe it in the language of the upper half; the gap between the two is where most of the work is.

The head-to-head trial is real

The cleanest study is the 2019 Dhaliwal randomized, double-blind trial: 44 participants, 12 weeks, 0.5% bakuchiol twice daily versus 0.5% retinol once daily. Both groups improved wrinkle surface area and hyperpigmentation, with more scaling and stinging reported in the retinol group.

That is useful evidence. It is not an entire category. A 2024 systematic review found 15 human clinical trials, but most were open-label, many used combination formulas, and the study designs were too heterogeneous for a clean pooled answer. “There is a promising trial” and “bakuchiol is clinically equivalent to retinoids” are not the same sentence.

Gentleness is the trade

For someone who repeatedly cannot tolerate a retinoid, a gentler product that is easier to use consistently may be worth more than a theoretically stronger bottle that spends half the year in a drawer. That is a real advantage. It is an adherence advantage, not proof that the evidence base has caught up with tretinoin or well-studied retinol.

Pregnancy is not a free pass

Bakuchiol is not a retinoid, but that fact does not establish pregnancy safety. Human pregnancy-safety data are insufficient. If pregnancy, breastfeeding, or preconception is the reason a retinoid is off the table, do not treat bakuchiol as an automatically cleared substitute; that is a clinician conversation.

Who might prefer it

Someone who has failed retinoids because of irritation, wants a gentler anti-photoaging option, and is comfortable with a smaller evidence base may reasonably try it. It is not a stealth upgrade on prescription tretinoin. Retinaldehyde, lower-strength retinoids, better moisturization, slower schedules, or simply excellent sunscreen may solve the actual problem more directly.

Where I land

Interesting with conditions. The head-to-head trial is good enough to take seriously; the broader category evidence is not strong enough to treat “plant retinol” as settled fact. Gentler is useful. Equivalent is a much bigger claim.

Sources: Dhaliwal et al., 2019 randomized double-blind bakuchiol-versus-retinol trial (PMID 29947134); Fanning et al., 2024 systematic review of human topical bakuchiol trials (PMID 38564402). Reviewed August 2026. General education, not individualized medical advice.